コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 urrence in estrogen receptor- positive (ER+) breast cancer tissue.
2 mor virus and a human retrovirus cloned from breast cancer tissue.
3 r suppressor and has oncogenic capacities in breast cancer tissue.
4 that control the expression of aromatase in breast cancer tissue.
5 thought that SF1 protein is not expressed in breast cancer tissue.
6 the nuclear proteins interacting with S1 in breast cancer tissue.
7 tabolic changes associated with EMT in human breast cancer tissue.
8 ttom-up spatial proteomics is explored using breast cancer tissue.
9 alysis in analysing metabolic changes in EMT breast cancer tissue.
10 nically relevant immune cell infiltration in breast cancer tissue.
11 growth factor receptor 2 (HER2) IHC-stained breast cancer tissue.
12 abundances are significantly altered within breast cancer tissue.
13 metal-tagged biomarker in a thin section of breast cancer tissue.
14 ers I.3/II, which are preferentially used in breast cancer tissue.
15 but not EGFR, was observed in HER2-amplified breast cancer tissues.
16 lates with centrosome amplification in human breast cancer tissues.
17 ethylation in human breast cell lines and T1 breast cancer tissues.
18 d from as low as 50-100 pg of total RNA from breast cancer tissues.
19 ated using 6 breast cancer cell lines and 10 breast cancer tissues.
20 EF (hSEF), is also expressed in a variety of breast cancer tissues.
21 ence of a variant phosphorolytic activity in breast cancer tissues.
22 cyclin D co-expression was observed in human breast cancer tissues.
23 er characterized by in situ hybridization to breast cancer tissues.
24 gene in breast cancer cell lines and primary breast cancer tissues.
25 UC-1 and erbB-2 were performed on 67 primary breast cancer tissues.
26 oidin domain-containing receptor 2 (DDR2) in breast cancer tissues.
27 locus in a different region of the genome of breast cancer tissues.
28 ressed in three breast cancer cell lines and breast cancer tissues.
29 related with beta-catenin and PKM2 levels in breast cancer tissues.
30 a notable lipid signature was identified in breast cancer tissues.
31 n studies, to dissect spatial domains within breast cancer tissues.
32 clinical applicability in a small cohort of breast cancer tissues.
33 ene signature" that is distinct from primary breast cancer tissues.
34 ression in normal breast tissues compared to breast cancer tissues.
35 RNA, is significantly overexpressed in human breast cancer tissues.
36 s increased levels of both KLF4 and PRMT5 in breast cancer tissues.
37 candidate for detection of MGA expression in breast cancer tissues.
38 was selectively and significantly higher in breast cancer tissues.
39 pression of UBR5 and MYC in human basal-type breast cancer tissues.
40 of breast cancer cell lines as well as human breast cancer tissues.
41 ntration of pVHL and accumulation of KLF4 in breast cancer tissues.
42 negatively correlated with CD8(+) T cells in breast cancer tissues.
43 miR-155 were frequently detected in invasive breast cancer tissues.
44 (815-53,714) and expressed by nearly half of breast cancers tissues.
46 tochemically) was significantly decreased in breast cancer tissues (although the transcript levels we
48 (eQTLs) obtained from normal breast tissue, breast cancer tissue and blood were used as genetic inst
49 ssion of RORalpha was downregulated in human breast cancer tissue and cell lines, and that reduced mR
50 correlate with ErbB3 levels in primary human breast cancer tissue and in a mouse model of ErbB2 mamma
52 tological studies of BRCA1 protein in frozen breast cancer tissue and MCF7 and HeLa cell lines reveal
56 to further characterize metabolic changes in breast cancer tissue and the tumor microenvironment.
57 coexpression patterns of hormonal markers in breast cancer tissue and their relationship with patholo
58 ECLUST on simulated ST datasets from a human breast cancer tissue and two real ST datasets from human
60 icantly, we also found that, out of 51 human breast cancer tissues and 10 normal controls examined, p
62 correlated both in normal breast tissue and breast cancer tissues and associated with overall surviv
63 -1 was also expressed at high levels in both breast cancer tissues and breast cancer cells when compa
64 and protein expression are down-regulated in breast cancer tissues and cell lines compared with adjac
71 sine kinase is absent or reduced in invasive breast cancer tissues and cell lines; its loss in breast
72 differentially expressed as a 1.35 kb RNA in breast cancer tissues and cell-lines, and in several nor
73 the direct measurement of this biomarker in breast cancer tissues and cells might serve as a prognos
74 the predicted E-cadherin-targeting miRNAs in breast cancer tissues and cells showed that miR-221 was
76 which is aberrantly upregulated in clinical breast cancer tissues and closely correlated with poor p
77 ase polymerase chain reaction in 915 primary breast cancer tissues and correlated with known clinicop
78 man glioblastoma cell line U87MG and primary breast cancer tissues and found that 26-45% of all genes
80 maging signal was increased significantly in breast cancer tissues and highly correlated with ex vivo
81 east cancer, demonstrable with primary human breast cancer tissues and human breast cancer cell lines
82 d that DNMT1 protein levels were elevated in breast cancer tissues and in MCF-7 breast cancer cells r
83 overexpression is found in 46 of 79 primary breast cancer tissues and is associated with high tumor
84 f ERalpha in breast cancer cell lines, human breast cancer tissues and Runx3(+/-) mouse mammary tumor
85 ficant difference in hGH mRNA levels between breast cancer tissues and their normal counterparts, alt
87 we investigated whether CHK is expressed in breast cancer tissues and whether it participates in the
88 matase (estrogen synthetase) is expressed in breast cancer tissue, and in situ expression of the enzy
89 essed in both cancer cell lines and advanced breast cancer tissues, and the levels of TRIM28 and TWIS
90 ariable in different breast cancer cells and breast cancer tissues, and was found to be localized in
92 sis showed that higher levels of sGCbeta1 in breast cancer tissues are correlated with greater surviv
95 protein p54(nrb)/Nono is highly expressed in breast cancer tissues as compared with the adjacent norm
96 expression in a significant number of human breast cancer tissues as well as in many established bre
99 en sensitive and resistant cells and between breast cancer tissues (available from The Cancer Genome
100 vances in the manufacturing of 3D bioprinted breast cancer tissue (BCT), many studies still suffer fr
102 test to identify truncated BRCA2 proteins in breast cancer tissue biopsies in vivo that does not use
104 trophil elastase was expressed by TAN within breast cancer tissues but not by breast cancer cells.
105 s were 37 kDa, whereas in a large portion of breast cancer tissues, but not normal control tissues, o
106 egrative spatial analysis of triple-negative breast cancer tissues by examining copy number alteratio
109 d HER2 are colocalized in plasma membrane of breast cancer tissue cells and breast cancer cell lines
110 to capture GPI-anchored proteins from human breast cancer tissues, cells, and serum for proteomic an
111 erences have been charted between normal and breast cancer tissues, changes in higher-order chromatin
112 e expression of IRF-1 and IRF-2 may occur in breast cancer tissue compared with normal breast tissue,
115 nd to have significantly lower expression in breast cancer tissues compared to paired normal breast t
116 c RNA) is upregulated in tamoxifen-resistant breast cancer tissues compared to their primary counterp
117 uctions and enhancements in the intensity in breast cancer tissues compared to uninvolved breast tiss
119 kinase, is significantly increased in human breast cancer tissues compared with normal and benign br
120 ession is up-regulated in distant metastatic breast cancer tissues compared with primary cancer tissu
122 turated and monounsaturated phospholipids in breast cancer tissues, consistent with external validati
125 ics were developed to classify malignancy of breast cancer tissues, demonstrating that X-ray/optical
127 The abundance of molecular profiling of breast cancer tissues entailed active research on molecu
128 found that the d-spacing of the EMT positive breast cancer tissue (FFPE (dewaxed)) is within the rang
129 ign Tissue Bank (BCCTB), a vital resource of breast cancer tissue for researchers to support and prom
130 Breast Cancer Project, and paraffin-embedded breast cancer tissues for 90 patients were available for
131 nefit rate, safety, and analysis of archival breast cancer tissues for molecular markers associated w
132 erse transcription-PCR analysis of 18 paired breast cancer tissues found that in 28% of the cancer sa
133 receptor and pSmad2 immunohistochemically in breast cancer tissue from 1,045 patients in the Shanghai
134 emistry was performed on adjacent normal and breast cancer tissues from 96 premenopausal women with k
135 ance of GLUT-1, GLS1, and GLS2 expression in breast cancer tissues from Jordanian patients, focusing
136 ming immunohistochemical staining in primary breast cancer tissues from patients with different stage
137 lar effects are noted with in vitro cultured breast cancer tissues from patients, but not with normal
139 A reduction of the expression of SnaH in breast cancer tissue further suggests a cancer-protectiv
140 sues and their normal counterparts, although breast cancer tissues generally appeared to have heterog
141 on pathway in different pathologic grades of breast cancer tissue has not been described thoroughly,
142 profiled its expression and localization in breast cancer tissues identifying prominent differences
143 (111In-MX-DTPA) BrE-3 to specifically target breast cancer tissue in patients, and the dosimetry deri
144 expression were also selectively induced in breast cancer tissues in transgenic mice expressing the
145 of p63 mRNA compared with other genotypes in breast cancer tissues, indicating that rs17506395 may be
150 We observed that IGF-1R, in triple-negative breast cancer tissues, is predominantly intracellular an
151 AKT) expression by immunohistochemistry in a breast cancer tissue microarray (n = 377) with approxima
152 the full panel images and information within breast cancer tissue microarray datasets using cyclic im
154 ections and formalin-fixed paraffin-embedded breast cancer tissue microarray samples as model systems
158 inhibitor (SLPI), were studied further with breast cancer tissue microarrays using a novel method of
159 Reclassification of breast cancer cells and breast cancer tissue microarrays with this system correl
164 analysis was not able to detect SF1 mRNA in breast cancer tissue or in SK-BR-3 cells, it is thought
166 niques to analyze expression of EI24/PIG8 in breast cancer tissue progression arrays and showed that
167 studies to be up-regulated in both lung and breast cancer tissues relative to normal adjacent tissue
169 CI: 42, 60]) but only 22 of 121 ER-negative breast cancer tissue samples (18% [95% CI: 12, 26]) were
170 rays demonstrated that 63 of 123 ER-positive breast cancer tissue samples (51% [95% CI: 42, 60]) but
171 n-2 protein expression was also decreased in breast cancer tissue samples as evaluated by immunohisto
172 ly, immunohistochemical staining of lung and breast cancer tissue samples demonstrated that increased
174 ance to our studies is our analysis of human breast cancer tissue samples that indicated association
175 indings suggest that the analysis of primary breast cancer tissue samples will be indispensable for t
176 ry-based proteomics, which allow analysis of breast cancer tissue samples, leading to the first large
177 overexpressed in approximately 50% of human breast cancer tissue samples, suggesting that regulation
178 rgeting 8 cancer proteins was performed on a breast cancer tissue section to illustrate the potential
179 ormalin-fixed paraffin-embedded (FFPE) human breast cancer tissue sections were stained for multiplex
182 ding is further confirmed from data in human breast cancer tissues showing that CNNM3 levels correlat
183 owed that elevated CDK11(p110) expression in breast cancer tissues significantly correlated with poor
184 approach by imaging Papanicolaou smears and breast cancer tissue slides over a large field-of-view o
185 stribution of MT1-MMP with Ln-5 in colon and breast cancer tissue specimens suggested a role for this
187 ase studies on mouse kidney tissue and human breast cancer tissue suggest that the PPI-regularized CN
189 levels were significantly higher in invasive breast cancer tissues than in breast adenocarcinoma tiss
190 expression was significantly higher in most breast cancer tissues than in normal breast tissues.
192 mpare gene expression profiles from the same breast cancer tissue that had been either frozen or FPE
193 omprehensive metabolic phenotyping method in breast cancer tissue that uses desorption electrospray i
194 elevated in HER2/neu-positive primary human breast cancer tissues that are known to be resistant to
195 the AI activity of a dual AI/SERM, while in breast cancer tissue the antiestrogenic SERM activity of
197 ty, and enabled the cellular architecture of breast cancer tissue to be characterized on the basis of
200 alyzing 188 normal breast and 1247 malignant breast cancer tissues, we observed the loss of KLLN in m
202 This study examines HER2 testing of primary breast cancer tissue when performed with immunohistochem
203 el gene that is overexpressed in ovarian and breast cancer tissues when compared with normal tissues.
204 ided evidence of the expression of UGT1A1 in breast cancer tissue, where a positive signal was observ
205 esults showed that MUC16 is overexpressed in breast cancer tissues whereas not expressed in non-neopl
206 ive (HER2+) but not in HER2-negative (HER2-) breast cancer tissues, whereas both HER2+ and HER2- tumo
207 generating PIP2, is positively expressed in breast cancer tissues, which correlates intimately with
208 owed us to differentiate between healthy and breast cancer tissues with high signal/noise ratios.
209 ine CSCs in formalin-fixed paraffin-embedded breast cancer tissue, with the goal of assessing the pro